The detection of colistin resistance in carbapenem resistant Klebsiella pneumoniae isolates


  • Ipek Koçer Department of Clinical Microbiology, Gaziantep University Faculty of Medicine, Gaziantep, Turkey
  • Yasemin Zer Department of Clinical Microbiology, Gaziantep University Faculty of Medicine, Gaziantep, Turkey
  • Ayse Buyuktas Department of Clinical Microbiology, Gaziantep University Faculty of Medicine, Gaziantep, Turkey



Antimicrobial susceptibility test, Klebsiella pneumoniae, Colistin


Background: Infections that develop with resistant Klebsiella pneumoniae have been associated with high morbidity and mortality. Problems in the treatment of these infections have required the use of new treatment options such as colistin in recent years. This study was carried out to contribute to routine applications by investigating the compatibility of methods commonly used in determining colistin susceptibility with the gold standard broth microdilution (BMD) method.

Methods: Colistin MIC values were determined by BMD, broth microdilution based commercial kit (Sensititre, ThermoFisher, USA), Vitek2 (bioMerieux, France) and gradient test (Bioanalyse, Turkey) in 128 carbapenem resistant K. pneumonaie strains isolated from various clinical samples sent from July 2018 to July 2019 to the microbiology laboratory.

Results: According to the BMD method, 62 (48.4%) of the isolates were susceptible and 66 (51.6%) were colistin resistant. Accepting BMD method as reference, very large error (to find a susceptible result in a reference test as susceptible) and large error (to detect a susceptible result in a reference test as resistant) ratios in broth microdilution based commercial kit, automated system and gradient test were found respectively as 0%, 15.1, 18.1 and 0, 6.4 and 9.6%. According to the ISO performance criteria, the commercial kit shows "acceptable performance" while the other two tests have a very large error rate of >10% and are considered as "unacceptable performance".

Conclusions: It was concluded that the ready kit we tested in laboratories with heavy workload could be used to determine the colistin susceptibility and the result determined in automated systems should be confirmed.


Satlin MJ, Chen L, Patel G, Gomez-Simmonds A, Weston G, Kim AC et al. Multicenter clinical and molecular epidemiological analysis of bacteremia due to carbapenem-resistant Enterobacteriaceae (CRE) in the CRE epicenter of the United States. Antimicrob agents chemotherapy. 2017;61(4):e02349-16.

Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet infect dis. 2013;13(9):785-96.

Kaye KS, Pogue JM, Tran TB, Nation RL, Li J. Agents of last resort: polymyxin resistance. Infect dis clin N Am. 2016;30(2):391-414.

Liu Y-Y, Wang Y, Walsh TR, Yi L-X, Zhang R, Spencer J et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet infect dis. 2016;16(2):161-8.

Yin W, Li H, Shen Y, Liu Z, Wang S, Shen Z et al. Novel plasmid-mediated colistin resistance gene mcr-3 in Escherichia coli. MBio. 2017;8(3):e00543-17.

Xavier BB, Lammens C, Ruhal R, Kumar-Singh S, Butaye P, Goossens H et al. Identification of a novel plasmid-mediated colistin-resistance gene, mcr-2, in Escherichia coli, Belgium, June 2016. Euro Surve Monthly. 2016;21(27):30280.

Wang X, Wang Y, Zhou Y, Li J, Yin W, Wang S et al. Emergence of a novel mobile colistin resistance gene, mcr-8, in NDM-producing Klebsiella pneumoniae. Emerging microbes infect. 2018;7(1):1-9.

Partridge SR, Di Pilato V, Doi Y, Feldgarden M, Haft DH, Klimke W et al. Proposal for assignment of allele numbers for mobile colistin resistance (mcr) genes. J Antimicrob Chemotherapy. 2018;73(10):2625-30.

The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 8.1 2018. Available at: http://www.eucast. org." . Accessed on 11 January 2021.

Standardization IOf. ISO 20776-2: 2007 (E). Clinical laboratory testing and in vitro diagnostic test systems. Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices. International Organization for Standardization Geneva, Switzerland. 2007.

Koçak CÖ, Hazırolan G. Karbapeneme Dirençli Klebsiella pneumoniae Klinik İzolatlarında Kolistin Direnci. Türk Mikrobiyoloji Cem Derg. 2019;49(1):17-23.

Organization WH. Central Asian and Eastern European surveillance of antimicrobial resistance: annual report 2017. Central Asian and Eastern European surveillance of antimicrobial resistance: annual report. 2017;2018.

Li Y, Sun Q-l, Shen Y, Zhang Y, Yang J-w, Shu L-b et al. Rapid increase in prevalence of carbapenem-resistant Enterobacteriaceae (CRE) and emergence of colistin resistance gene mcr-1 in CRE in a hospital in Henan, China. J clin microbiol. 2018;56(4):e01932-17.

Rojas LJ, Salim M, Cober E, Richter SS, Perez F, Salata RA et al. Colistin resistance in carbapenem-resistant Klebsiella pneumoniae: laboratory detection and impact on mortality. Clin Infect Dis. 2017;64(6):711-8.

European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2014. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2015.

Süzük Yıldız S, Kaşkatepe B, Şimşek H, Sarıgüzel FM. High rate of colistin and fosfomycin resistance among carbapenemase-producing Enterobacteriaceae in Turkey. Acta microbiologica et immunologica Hungarica. 2019;66(1):103-12.

Menekşe Ş, Çağ Y, Işık ME, Şahin S, Hacıseyitoğlu D, Can F et al. The effect of colistin resistance and other predictors on fatality among patients with bloodstream infections due to Klebsiella pneumoniae in an OXA-48 dominant region. Int J Infect Dis. 2019;86:208-11.

Capone A, Giannella M, Fortini D, Giordano A, Meledandri M, Ballardini M et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect. 2013;19(1):E23-E30.

Monaco M, Giani T, Raffone M, Arena F, Garcia-Fernandez A, Pollini S et al. Colistin resistance superimposed to endemic carbapenem-resistant Klebsiella pneumoniae: a rapidly evolving problem in Italy, November 2013 to April 2014. Eurosurveillance. 2014;19(42):20939.

Kaza P, Mahindroo J, Veeraraghavan B, Mavuduru RS, Mohan B, Taneja N. Evaluation of risk factors for colistin resistance among uropathogenic isolates of Escherichia coli and Klebsiella pneumoniae: a case-control study. J med microbiol. 2019;68(6):837-47.

Guducuoglu H, Gursoy NC, Yakupogullari Y, Parlak M, Karasin G, Sunnetcioglu M, et al. Hospital outbreak of a colistin-resistant, NDM-1-and OXA-48-producing Klebsiella pneumoniae: high mortality from pandrug resistance. Microbial Drug Resistance. 2018;24(7):966-72.

Giacobbe D, Del Bono V, Trecarichi E, De Rosa FG, Giannella M, Bassetti M et al. Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case–control–control study. Clin Microbiol Infect. 2015;21(12):1106.e1-8.






Original Research Articles